Grifols ADR earnings beat, revenue topped estimates
#Grifols ADR #Earnings Beat #Revenue Estimates #NASDAQ: GRFS #Biopharmaceutical #Q4 Results #Financial Health #Stock Performance
📌 Key Takeaways
- Grifols ADR beat Q4 EPS estimates with $0.30 vs $0.29 consensus
- Quarterly revenue exceeded expectations at $2.34B vs $2.25B forecast
- Stock has gained 1.24% in 3 months and 6.16% in 12 months
- Company maintains 'great performance' financial health rating
📖 Full Retelling
Spanish biopharmaceutical company Grifols ADR (NASDAQ: GRFS) reported fourth quarter earnings per share of $0.30, beating analyst estimates of $0.29, with quarterly revenue reaching $2.34 billion, exceeding the $2.25 billion consensus estimate in its latest financial results released on February 26, 2026. The company's stock performance has been positive, with shares closing at $8.96, up 1.24% in the last three months and 6.16% over the past year, reflecting investor confidence in the company's financial trajectory. Despite mixed analyst sentiment in recent months, with zero positive earnings per share revisions and one negative revision over the last 90 days, Grifols has maintained a 'great performance' financial health rating according to InvestingPro's assessment.
🏷️ Themes
Earnings Results, Biopharmaceutical Industry, Financial Performance
📚 Related People & Topics
Biopharmaceutical
Drug made from biological source
A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, alle...
Entity Intersection Graph
Connections for Biopharmaceutical:
🌐
Insider trading
2 shared
🌐
Cystic fibrosis
1 shared
🌐
Clinical trial
1 shared
🏢
RBC Capital Markets
1 shared
🌐
Chief strategy officer
1 shared
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Netflix declines to match Paramount Skydance bid for Warner Bros Dorsey’s Block slashes workforce 40% to embrace AI-native future, shares gain S&P 500, Nasdaq end in the red as Nvidia drags chip stocks lower Gold prices mixed as U.S.-Iran nuclear talks end after ’significant progress’ (South Africa Philippines Nigeria) Grifols ADR earnings beat, revenue topped estimates By Investing.com Earnings Published 02/26/2026, 07:25 PM Grifols ADR earnings beat, revenue topped estimates 0 GRFS -3.14% Investing.com - Grifols ADR (NASDAQ: GRFS ) reported fourth quarter EPS of $0.30, better than the analyst estimate of $0.29. Revenue for the quarter came in at $2.34B versus the consensus estimate of $2.25B. Grifols ADR’s stock price closed at $8.96. It is up 1.24% in the last 3 months and up 6.16% in the last 12 months. Grifols ADR saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Grifols ADR’s stock price’s past reactions to earnings here . According to InvestingPro , Grifols ADR’s Financial Health score is " great performance ". Check out Grifols ADR’s recent earnings performance , and Grifols ADR’s financials here . Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Read full article at source